jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Anti-SM Antibodies by EIA

Blood
image

Report in 48Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Detects anti-Smith antibodies.

₹2,368₹3,383

30% OFF

Anti-SM Antibodies by EIA - Comprehensive Medical Test Guide

  • Why is it done?
    • Test Overview: This test measures anti-Smith (anti-SM) antibodies, which are autoantibodies that target Smith antigen, a protein component of the cell nucleus. The test uses enzyme immunoassay (EIA) technology to detect and quantify these antibodies in blood serum.
    • Primary Indications: Diagnostic aid for systemic lupus erythematosus (SLE); highly specific marker for SLE confirmation; evaluation of patients with suspected autoimmune rheumatologic diseases; assessment of ANA-positive patients; monitoring disease activity and progression in known SLE patients.
    • Clinical Circumstances: Performed when patients present with signs and symptoms suggestive of SLE (photosensitivity, malar rash, arthritis, serositis, nephritis); as part of initial autoimmune panel workup; during initial diagnosis establishment; periodically during follow-up care; when other lupus manifestations are present; in patients with family history of SLE or autoimmune disease.
  • Normal Range
    • Reference Values: Negative or Less than 1.0 IU/mL (or < 0.5 IU/mL depending on laboratory reference range); results may also be reported as negative, borderline, or positive based on laboratory-specific cutoffs.
    • Units of Measurement: IU/mL (International Units per milliliter) or may be reported as a qualitative result (positive/negative); some laboratories use optical density (OD) values.
    • Result Interpretation: Negative: < 1.0 IU/mL = Absence of anti-SM antibodies (normal result); Borderline: 0.9-1.1 IU/mL = Indeterminate, may require repeat testing or clinical correlation; Positive: > 1.0 IU/mL = Presence of anti-SM antibodies (abnormal result).
    • What Normal Means: Negative result does not exclude SLE but makes it less likely; reduces probability of SLE diagnosis when combined with clinical findings; may indicate patient does not have SLE or has seronegative lupus.
    • What Abnormal Means: Positive result is highly specific for SLE (95-98% specificity); present in approximately 30-40% of SLE patients; more specific than ANA alone; indicates increased likelihood of SLE diagnosis when combined with clinical and laboratory findings.
  • Interpretation
    • Negative Result (< 1.0 IU/mL): Suggests absence of anti-SM antibodies; does not rule out SLE as approximately 60-70% of SLE patients are anti-SM negative; may indicate seronegative lupus or alternative diagnosis; negative result in presence of ANA positivity and clinical symptoms requires further investigation; does not exclude other autoimmune conditions.
    • Positive Result (> 1.0 IU/mL): Highly specific for SLE diagnosis (95-98% specificity); when positive with appropriate clinical findings, strongly supports SLE diagnosis; associated with higher specificity than anti-RNP or anti-Ro/La antibodies; rarely found in other autoimmune conditions; appears to be stable over time in SLE patients; may correlate with certain SLE manifestations.
    • Titer Levels: In quantitative EIA, higher antibody titers do not necessarily correlate with disease severity; high positive values indicate presence of antibodies but do not predict clinical course; moderate to very high positive values all indicate SLE-specific antibodies; individual laboratory reference ranges must be consulted for interpretation.
    • Clinical Correlation: Result must be interpreted with clinical presentation, ANA status, complement levels, and other laboratory findings; positive anti-SM with positive ANA and clinical symptoms strongly supports SLE diagnosis; anti-SM alone cannot diagnose SLE without clinical correlation; clinical judgment by physician is essential for diagnosis.
    • Factors Affecting Results: Laboratory methodology and assay platform differences; variation in cutoff values between laboratories; specimen handling and storage conditions; timing of test during disease course; certain medications (immunosuppressants, biologics) may affect antibody levels; hemolysis or lipemia may interfere with testing; patient age and ethnicity may influence antibody presence.
    • Disease Association: Anti-SM is considered a specific marker for SLE; rarely present in other connective tissue diseases; when positive, increases pre-test probability of SLE substantially; more specific than anti-DNA; may appear before clinical SLE manifestations; presence can aid in early diagnosis before overt clinical features develop.
  • Associated Organs
    • Primary Organ Systems Involved: Immune system (autoimmune mechanism); skin (photosensitive rashes, malar rash); joints (arthritis, arthralgia); kidneys (lupus nephritis); heart and serosal membranes (pericarditis, pleuritis); hematologic system (cytopenias); nervous system (cognitive dysfunction, seizures); lungs (pleuritis, pulmonary hemorrhage).
    • Systemic Lupus Erythematosus (SLE): Primary disease associated with anti-SM antibodies; multi-system autoimmune disease characterized by dysregulated immune response; positive anti-SM strongly supports SLE diagnosis; associated with specific SLE diagnostic criteria; indicates need for comprehensive SLE workup and management.
    • Other Associated Conditions: Lupus nephritis (kidney involvement); serositis with pleuritis and pericarditis; cutaneous manifestations; hematologic complications (anemia, thrombocytopenia, leukopenia); neuropsychiatric lupus; secondary conditions may develop including infections due to immunosuppression.
    • Potential Complications: Untreated SLE may progress to severe organ damage, particularly renal failure; cardiovascular complications including increased atherosclerosis risk; hematologic complications including thrombotic events; infections secondary to immunosuppressive treatment; osteoporosis from prolonged corticosteroid use; increased pregnancy complications and miscarriage risk (antiphospholipid antibodies may coexist); neurological complications; blindness from retinal vasculitis.
    • Monitoring Implications: Positive anti-SM necessitates regular monitoring of kidney function (urinalysis, creatinine); periodic assessment of blood counts; evaluation of complement levels; monitoring for clinical manifestations; periodic imaging or biopsy as clinically indicated; assessment of medication efficacy and toxicity.
  • Follow-up Tests
    • Initial Confirmatory Tests: Antinuclear antibody (ANA) if not already performed; complement levels (C3, C4) to assess complement consumption; anti-double stranded DNA (anti-dsDNA) antibodies; anti-RNP (anti-U1 RNP) antibodies; anti-Ro/La antibodies; complete metabolic panel for baseline renal and hepatic function.
    • Organ-Specific Evaluation: Urinalysis and urine protein quantification for renal involvement; serum creatinine and estimated glomerular filtration rate (eGFR) for kidney function; complete blood count (CBC) to assess cytopenias; renal biopsy if lupus nephritis suspected; chest X-ray for pulmonary or cardiac involvement; echocardiography if cardiac disease suspected.
    • Coagulation and Thrombosis Assessment: Antiphospholipid antibodies (anticardiolipin, beta-2 glycoprotein I) if thrombosis or pregnancy complications present; lupus anticoagulant testing; prothrombin time (PT) and activated partial thromboplastin time (aPTT) if indicated.
    • Monitoring During Treatment: Repeat anti-dsDNA and complement levels every 3-6 months or as clinically indicated; periodic CBC and metabolic panel; urinalysis monitoring for proteinuria; periodic renal function assessment; monitoring for medication side effects; assessment of disease activity markers; response to immunosuppressive therapy.
    • Additional Antibody Testing: Anti-C1q antibodies (associated with lupus nephritis); anti-histone antibodies (drug-induced lupus); antiribonucleoprotein (anti-nRNP) panel; anti-phospholipid antibodies; anti-mitochondrial antibodies if autoimmune hepatitis suspected; thyroid antibodies if thyroid involvement suspected.
    • Imaging and Biopsy Follow-up: Renal biopsy for histological classification of lupus nephritis; skin biopsy for discoid lesions; MRI brain if neuropsychiatric lupus suspected; ultrasound or echocardiography for cardiac involvement; chest CT for pulmonary disease evaluation.
    • Follow-up Frequency: Initial workup should be comprehensive when anti-SM positive; routine monitoring typically every 3-6 months in stable patients; more frequent monitoring during active disease or treatment changes; individualized based on disease severity and organ involvement; lifelong monitoring necessary as SLE is chronic relapsing-remitting condition.
  • Fasting Required?
    • Fasting Requirement: No - Fasting is NOT required for anti-SM antibody testing by EIA. This is a serology test that measures antibodies and does not require fasting status.
    • Patient Preparation: Patient may eat and drink normally before the test; no dietary restrictions necessary; may take regular medications as prescribed; no special pre-test preparation required; test can be performed at any time of day.
    • Specimen Collection: Blood specimen (serum) drawn via venipuncture into standard collection tube; no special tube or additives required (typically serum separator tube); approximately 5-10 mL of blood collected; specimen should be handled according to laboratory protocol; proper labeling and chain of custody must be maintained.
    • Special Instructions: Inform laboratory of any active infections or recent vaccinations that may affect results; notify healthcare provider of all current medications; inform if patient is pregnant (may affect antibody levels); provide accurate history of any rheumatologic symptoms; specify timing if test ordered during acute flare versus stable disease.
    • Medications and Supplements: Continue all regular medications as scheduled; no medications need to be stopped for this test; immunosuppressive medications should not be discontinued without physician approval; herbal supplements may be continued; anticoagulants do not affect antibody testing; inform phlebotomist of any bleeding disorders.
    • Other Considerations: Test may be ordered as part of comprehensive panel, which may have different fasting requirements; if ordered with other tests requiring fasting, follow most restrictive requirement; specimen stability important - process promptly; Results typically available within 2-7 business days depending on laboratory; discuss any concerns with healthcare provider before test.

How our test process works!

customers
customers